2024
Derivation of an Annualized Claims-Based Major Adverse Cardiovascular Event Estimator in Type 2 Diabetes
McCoy R, Swarna K, Deng Y, Herrin J, Ross J, Kent D, Borah B, Crown W, Montori V, Umpierrez G, Galindo R, Brito J, Mickelson M, Polley E. Derivation of an Annualized Claims-Based Major Adverse Cardiovascular Event Estimator in Type 2 Diabetes. JACC Advances 2024, 3: 100852. PMID: 38939660, PMCID: PMC11198625, DOI: 10.1016/j.jacadv.2024.100852.Peer-Reviewed Original ResearchType 2 diabetesMedicare fee-for-service planClaims-based prediction modelPopulation risk stratificationRisk of Major Adverse Cardiovascular EventsMajor adverse cardiovascular eventsNon-Hispanic whitesFee-for-service plansStudy cohortClinical trials of cardiovascular diseaseCox proportional hazards modelsProportional hazards modelCare populationHealth systemPrimary preventionMedicare AdvantageParticipant identificationPayer levelPharmacy claimsDecentralized clinical trialsHazards modelCardiovascular diseaseRisk predictionMedicarePatient population
2021
Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial
Vu K, Zhou J, Everhart A, Desai N, Herrin J, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial. BMC Nephrology 2021, 22: 284. PMID: 34419007, PMCID: PMC8379779, DOI: 10.1186/s12882-021-02491-y.Peer-Reviewed Original ResearchConceptsErythropoiesis-stimulating agentsChronic kidney diseaseEpoetin alfaDarbepoetin alfaTREAT trialTypes of ESAsNew clinical evidencePrimary care physiciansMedicare AdvantageUptake of evidenceCare physiciansAnemia treatmentClinical evidenceKidney diseasePhysician genderMedicare feeUnsafe treatmentSegmented regression approachStudy periodPhysiciansService populationConsistent changesAlfaHigher useTreatmentComparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019
McCoy RG, Van Houten HK, Deng Y, Mandic PK, Ross JS, Montori VM, Shah ND. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019. JAMA Network Open 2021, 4: e2035792. PMID: 33523188, PMCID: PMC7851726, DOI: 10.1001/jamanetworkopen.2020.35792.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsDipeptidyl peptidase-4 inhibitorsCommercial insurance beneficiariesMedicare Advantage beneficiariesDPP-4i treatmentGLP-1RAsType 2 diabetesInsurance beneficiariesMedicare AdvantageGlucose levelsGlucagonlike Peptide-1 Receptor AgonistsPeptide-1 receptor agonistsHealth plansCommercial health insurance plansGLP-1RA treatmentRetrospective cohort studyCotransporter 2 inhibitorsInitiation of treatmentPeptidase-4 inhibitorsLow-income patientsSeparate logistic regression modelsAdministrative claims dataCommercial health plansAdjusted annual rateLogistic regression models
2019
Rates of Physician Coprescribing of Opioids and Benzodiazepines After the Release of the Centers for Disease Control and Prevention Guidelines in 2016
Jeffery MM, Hooten WM, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Rates of Physician Coprescribing of Opioids and Benzodiazepines After the Release of the Centers for Disease Control and Prevention Guidelines in 2016. JAMA Network Open 2019, 2: e198325. PMID: 31373650, PMCID: PMC6681551, DOI: 10.1001/jamanetworkopen.2019.8325.Peer-Reviewed Original ResearchConceptsLong-term opioid useOpioid usePrevention guidelinesMA groupDisease controlCoprescription of opioidsRetrospective cohort studyUS national databaseInsurance groupsMedicare AdvantageSickle cell diseaseGuideline releasePrescription daysPrescribed opioidsBenzodiazepine prescriptionsCohort studyMedian agePharmacy claimsChronic painCell diseaseCoprescriptionMAIN OUTCOMESame clinicianClaims dataHospice careGeneric and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016
Ross JS, Rohde S, Sangaralingham L, Brito JP, Choi L, Dutcher SK, Graham DJ, Jenkins MR, Lipska KJ, Mendoza M, Qiang Y, Wang Z, Wu Y, Yao X, Shah ND. Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016. The Journal Of Clinical Endocrinology & Metabolism 2019, 104: 2305-2314. PMID: 30690529, DOI: 10.1210/jc.2018-02197.Peer-Reviewed Original ResearchConceptsBrand-name useDrug useMedicare AdvantageThyroid hormone replacement therapyLarge administrative claims databaseBeneficiary populationAdministrative claims databaseHormone replacement therapyCertain patient characteristicsMedicare Part DPrescriber specialtyPatient characteristicsPrescriber characteristicsClaims databaseReplacement therapyGeneric levothyroxineWhite raceHealth plansOlder adultsHormone drugsInsurance coverageProduct useLevothyroxineNational dataPart D